National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 5 of 1989)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, addresses the administration and funding of healthcare services, including the provision of pharmaceutical benefits to Australian citizens. This Act was introduced to ensure that all Australians have access to essential medications at an affordable price, thus reducing the financial burden of healthcare on individuals. The Pharmaceutical Benefits Declaration under subsection 85(2AA), made by Ian James McNeil, the First Assistant Secretary of the Health Benefits Division, Department of Community Services and Health, on 18 May 1989, aims to cease the application of Part VII of the National Health Act 1953 to certain drugs and medicinal preparations listed in the Schedule, thereby excluding them from the benefits provided under the Pharmaceutical Benefits Scheme. The policy objective of this declaration is to refine and focus the scope of the scheme by removing medications that are no longer considered essential or have alternative treatment options available.

Scope and Application

The Pharmaceutical Benefits Declaration under Sub-section 85(2AA) of the National Health Act 1953, specifically the legislative instrument No. PB5 of 1989, pertains to the exclusion of certain drugs and medicinal preparations from the ambit of Part VII of the National Health Act 1953. This Declaration applies to the listed drugs and medicinal preparations, namely Ammonium Chloride B.P., Benzyl Benzoate B.P., Intraperitoneal Dialysis Solutions B.P., and Sulphadimidine Tablets B.P., which are detailed in the Schedule attached to the Declaration. This exclusion from the Pharmaceutical Benefits Scheme takes effect from 18 May 1989, as stipulated in the Declaration made by Ian James McNeil, the First Assistant Secretary of the Health Benefits Division, Department of Community Services and Health, and acting as the Delegate of the Minister of State for Community Services and Health. The scope of this legislation is confined to the Commonwealth of Australia, thereby impacting all entities and individuals involved in the provision or procurement of these specified pharmaceutical products within Australia. There are no stated exclusions, exemptions, or thresholds in this particular Declaration, which directly affects the pharmaceutical industry and healthcare providers by altering the eligibility of certain drugs for government subsidies. The application of the Act may be further extended or restricted through subsequent subordinate instruments issued under the authority of the National Health Act 1953.

Key Provisions

The key provisions of this legislative instrument, the Pharmaceutical Benefits Declaration Under Sub-section 85 (2AA), are outlined in sections 1 and 2. Section 1 specifies that this Declaration will take effect on 18 May 1989. Section 2 then goes on to detail the drugs and medicinal preparations listed in the Schedule to the Declaration, which will cease to be covered under Part VII of the National Health Act 1953 from the date of the Declaration's operation. These drugs include Ammonium Chloride B.P., Benzyl Benzoate B.P., Intraperitoneal Dialysis Solutions B.P. C. 1973, and Sulphadimidine Tablets B.P. The obligations imposed by this Act on the relevant parties are primarily administrative and notification-based. The Act requires that the specified drugs and preparations, as listed in the Schedule, are to be removed from the list of items covered under Part VII of the National Health Act 1953. This necessitates administrative updates to the relevant databases and communications with healthcare providers and suppliers to ensure compliance with the new legislation. Breach of the provisions set out in this Declaration could result in legal consequences, though the specific nature of these consequences is not detailed within the text of the instrument. Generally, failure to comply with declarations made under the authority of the National Health Act 1953 could lead to civil or criminal penalties, depending on the severity and intent behind the breach. Such penalties might include fines or other forms of legal sanctions, but the exact penalties would need to be referred to within the broader context of the National Health Act 1953 and any relevant subsidiary legislation.